Filter Results :

Your search for drugs returned 1279 reports

Sort by


Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

06 Jan 2017  |  Published by:  MarketsandMarkets
The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.  In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area...

$ 5,650.00

Read More

Hyperparathyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hyperparathyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hyperparathyroidism Report is to understand ...

$ 2,000.00

Read More

Hyperthyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hyperthyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hyperthyroidism Report is to understand the mark...

$ 2,000.00

Read More

Hyperuricemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hyperuricemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hyperuricemia Report is to understand the market a...

$ 2,000.00

Read More

Hypocalcemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hypocalcemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hypocalcemia Report is to understand the market and...

$ 2,000.00

Read More

Hyponatremia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hyponatremia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hyponatremia Report is to understand the market and...

$ 2,000.00

Read More

Hypoparathyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hypoparathyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hypoparathyroidism Report is to understand th...

$ 2,000.00

Read More

Hypophosphatemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hypophosphatemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hypophosphatemia Report is to understand the ma...

$ 2,000.00

Read More

Hypopituitarism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hypopituitarism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hypopituitarism Report is to understand the mark...

$ 2,000.00

Read More

Hypotension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hypotension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hypotension Report is to understand the market and p...

$ 2,000.00

Read More

Hypothyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Hypothyroidism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hypothyroidism Report is to understand the market...

$ 2,000.00

Read More

Ichthyosis Vulgaris-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Ichthyosis Vulgaris-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Ichthyosis Vulgaris Report is to understand ...

$ 2,000.00

Read More

Idiopathic (Essential) Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Idiopathic (Essential) Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Idiopathic (Essential) Hyper...

$ 2,000.00

Read More

Idiopathic Pulmonary Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Idiopathic Pulmonary Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Idiopathic Pulmonary Fibrosis Repo...

$ 2,000.00

Read More

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

01 Jan 2017  |  Published by:  DelveInsight
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective o...

$ 2,000.00

Read More
Total 1279 records.